Gyre Therapeutics, Inc. Derivative Liability
Gyre Therapeutics, Inc. (GYRE) had Derivative Liability of $0 as of 2018-09-30, per its 10-Q filed 2018-11-01.
Discontinued › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2019-03-08
- 2018-09-30: Derivative Liability $0.00.
- 2018-06-30: Derivative Liability $0.00.
- 2018-03-31: Derivative Liability $0.00.
- 2017-12-31: Derivative Liability $0.00.
| Period end | Derivative Liability |
|---|---|
| 2018-09-30 | $0.00 10-Q · filed 2018-11-01 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-02 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-03 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |